VA-005 Clinical Outcomes of VIGIV Treatment of Smallpox Vaccination Complications or Vaccinia Infection
← catalyst calendarNCT01374984 · readout ≤ 377 d
Sponsored by Emergent BioSolutions (industry) · EBS — their whole pipeline →. With Centers for Disease Control and Prevention.
Phase
—
Status
Enrolling by invitation
Study type
Observational
Enrollment
100estimated
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | Aug 2007 | actual | When the study began enrolling |
| Primary completion | Aug 2027 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Aug 2028 | estimated | The whole study's end, after follow-up |
| First posted | 2011-06-17 | estimated | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-05-12 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Complication of Smallpox Vaccination
Intervention
- Biological: VIGIV — also filed as Vaccinia Immune Globulin Intravenous (Human)
Primary outcome
what the primary-completion date above is the date OFResolution of vaccinia infection complications
measured At hospital discharge (if not fully resolved at discharge then 1 month or 6 months as applicable)
Permalink · EBS's whole pipeline · Catalyst calendar · Every registered study · What changed